[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSWJrezTqzg1XriCA7TPP6HAbigqfTsELDbN6KwnKfAQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"University of Palermo",[4],140,false,25,4,47782,9,111,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Non-celiac Wheat Sensitivity",12,{"name":18,"count":19},"Non-celiac Gluten Sensitivity",6,{"name":21,"count":22},"Healthy Participants",5,{"name":24,"count":9},"Celiac Disease",{"name":26,"count":9},"Endometrial Polyp",{"name":28,"count":9},"Endometrial Diseases",{"name":30,"count":31},"Athletes",3,{"name":33,"count":31},"Healthy",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05999773","SGLT-2 Inhibitors in the Treatment of Ascites","2025-07-15","SGLT2 inhibitor",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06442280","SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF","2026-01-31","Dapagliflozin",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06985186","Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","2026-06","Ultra-Long GnRH Agonists + Letrozole",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07100613","Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus","2027-10-01","Clobetasol Patch",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,115,139,157,175,193,220,238,256,281,325,350,376,401,422,451,469,487,505,529,547,565,586,604,622,640,658,676,702,726,753,771,796,823,841,868,886,911,935,972,995,1021,1046,1073],{"intervention":64,"totalTrials":31,"cells":65},"Furosemide",{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":73,"PHASE4":87,"NA":113},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":68},[75],{"nctId":76,"briefTitle":77,"status":78,"phases":79,"primaryCompletion":80,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":86},"NCT04628325","Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)","COMPLETED",[59],"2019-06-30","2020-05-01","2017-03-01",136,[85],"Heart Failure，Congestive",[64],{"trials":88,"activeCount":112,"soonestReadout":43},[89,99],{"nctId":90,"briefTitle":91,"status":78,"phases":92,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"NCT01419132","Troponin I Release After High Diuretic Doses",[60],"2011-09","2011-08",60,[97],"ADHF",[64,64],{"nctId":41,"briefTitle":42,"status":100,"phases":101,"primaryCompletion":43,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":110},"NOT_YET_RECRUITING",[60],"2026-03-30","2024-06",544,[106,107,108,109],"Heart Failure Acute","Diabetes Type 2","Heart Failure With Reduced Ejection Fraction","Heart Failure With Preserved Ejection Fraction",[44,111,64],"Hypertonic Saline Solution, 1 Ml",1,{"trials":114,"activeCount":68},[],{"intervention":49,"totalTrials":112,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":137},{"trials":118,"activeCount":68},[],{"trials":120,"activeCount":68},[],{"trials":122,"activeCount":68},[],{"trials":124,"activeCount":68},[],{"trials":126,"activeCount":112,"soonestReadout":48},[127],{"nctId":46,"briefTitle":47,"status":100,"phases":128,"primaryCompletion":48,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},[60],"2026-12","2025-06",162,[133,134],"Adenomyosis of Uterus","Infertility Assisted Reproductive Technology",[49,136],"Ultra-Long GnRH Agonists",{"trials":138,"activeCount":68},[],{"intervention":136,"totalTrials":112,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":155},{"trials":142,"activeCount":68},[],{"trials":144,"activeCount":68},[],{"trials":146,"activeCount":68},[],{"trials":148,"activeCount":68},[],{"trials":150,"activeCount":112,"soonestReadout":48},[151],{"nctId":46,"briefTitle":47,"status":100,"phases":152,"primaryCompletion":48,"completion":129,"start":130,"enrollment":131,"conditions":153,"interventions":154},[60],[133,134],[49,136],{"trials":156,"activeCount":68},[],{"intervention":44,"totalTrials":112,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":173},{"trials":160,"activeCount":68},[],{"trials":162,"activeCount":68},[],{"trials":164,"activeCount":68},[],{"trials":166,"activeCount":68},[],{"trials":168,"activeCount":112,"soonestReadout":43},[169],{"nctId":41,"briefTitle":42,"status":100,"phases":170,"primaryCompletion":43,"completion":102,"start":103,"enrollment":104,"conditions":171,"interventions":172},[60],[106,107,108,109],[44,111,64],{"trials":174,"activeCount":68},[],{"intervention":111,"totalTrials":112,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":191},{"trials":178,"activeCount":68},[],{"trials":180,"activeCount":68},[],{"trials":182,"activeCount":68},[],{"trials":184,"activeCount":68},[],{"trials":186,"activeCount":112,"soonestReadout":43},[187],{"nctId":41,"briefTitle":42,"status":100,"phases":188,"primaryCompletion":43,"completion":102,"start":103,"enrollment":104,"conditions":189,"interventions":190},[60],[106,107,108,109],[44,111,64],{"trials":192,"activeCount":68},[],{"intervention":54,"totalTrials":112,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":196,"activeCount":68},[],{"trials":198,"activeCount":68},[],{"trials":200,"activeCount":112,"soonestReadout":53},[201],{"nctId":51,"briefTitle":52,"status":202,"phases":203,"primaryCompletion":53,"completion":53,"start":204,"enrollment":205,"conditions":206,"interventions":211},"RECRUITING",[58],"2024-09-04",45,[207,208,209,210],"Oral Lichen Planus","Oral Lichen Planus Related Stress","Oral Mucosal Disease","Oral Pain",[54,212,213],"Clobetasol + Resveratrol Patch","Clobetasol in Orabase",{"trials":215,"activeCount":68},[],{"trials":217,"activeCount":68},[],{"trials":219,"activeCount":68},[],{"intervention":212,"totalTrials":112,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":223,"activeCount":68},[],{"trials":225,"activeCount":68},[],{"trials":227,"activeCount":112,"soonestReadout":53},[228],{"nctId":51,"briefTitle":52,"status":202,"phases":229,"primaryCompletion":53,"completion":53,"start":204,"enrollment":205,"conditions":230,"interventions":231},[58],[207,208,209,210],[54,212,213],{"trials":233,"activeCount":68},[],{"trials":235,"activeCount":68},[],{"trials":237,"activeCount":68},[],{"intervention":213,"totalTrials":112,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":241,"activeCount":68},[],{"trials":243,"activeCount":68},[],{"trials":245,"activeCount":112,"soonestReadout":53},[246],{"nctId":51,"briefTitle":52,"status":202,"phases":247,"primaryCompletion":53,"completion":53,"start":204,"enrollment":205,"conditions":248,"interventions":249},[58],[207,208,209,210],[54,212,213],{"trials":251,"activeCount":68},[],{"trials":253,"activeCount":68},[],{"trials":255,"activeCount":68},[],{"intervention":39,"totalTrials":112,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":259,"activeCount":68},[],{"trials":261,"activeCount":68},[],{"trials":263,"activeCount":68},[],{"trials":265,"activeCount":68},[],{"trials":267,"activeCount":68},[],{"trials":269,"activeCount":112,"soonestReadout":38},[270],{"nctId":36,"briefTitle":37,"status":271,"phases":272,"primaryCompletion":38,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":280},"ACTIVE_NOT_RECRUITING",[],"2026-12-31","2023-07-15",40,[277,278,279],"Ascites Hepatic","Cirrhosis, Liver","Diabete Type 2",[39],{"intervention":282,"totalTrials":283,"cells":284},"Metformin",2,{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":323},{"trials":286,"activeCount":68},[],{"trials":288,"activeCount":68},[],{"trials":290,"activeCount":68},[],{"trials":292,"activeCount":68},[],{"trials":294,"activeCount":68},[295,310],{"nctId":296,"briefTitle":297,"status":78,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT03824002","Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables",[60],"2017-10-01","2018-04-20","2017-04-01",92,[304],"Diabetes Mellitus",[306,307,308,282,309],"Dulaglutide","Aspart insulin","Glargine","Repaglinide",{"nctId":311,"briefTitle":312,"status":313,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":321},"NCT03377335","Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes","UNKNOWN",[60],"2018-12","2019-01","2017-12-22",186,[320],"Type 2 Diabetes Mellitus",[322,282],"Dapagliflozin 10mg",{"trials":324,"activeCount":68},[],{"intervention":326,"totalTrials":112,"cells":327},"Nomegestrol Acetate\u002FEstradiol 2.5mg\u002F1.5mg",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":348},{"trials":329,"activeCount":68},[],{"trials":331,"activeCount":68},[],{"trials":333,"activeCount":68},[],{"trials":335,"activeCount":68},[],{"trials":337,"activeCount":68},[338],{"nctId":339,"briefTitle":340,"status":78,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT06316219","The Use of Nomegestrol Acetate\u002FEstradiol in Random Start Rapid Endometrial Preparation",[60],"2023-08-01","2024-03-01","2023-01-01",80,[26,28],[326],{"trials":349,"activeCount":68},[],{"intervention":351,"totalTrials":112,"cells":352},"Pasireotide 0.6 MG\u002FML",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":374},{"trials":354,"activeCount":68},[],{"trials":356,"activeCount":68},[],{"trials":358,"activeCount":68},[],{"trials":360,"activeCount":68},[],{"trials":362,"activeCount":68},[363],{"nctId":364,"briefTitle":365,"status":78,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":373},"NCT03080181","Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment",[60],"2016-12-30","2017-01-28","2013-05",24,[372],"Cushing Disease",[351],{"trials":375,"activeCount":68},[],{"intervention":377,"totalTrials":112,"cells":378},"Ezetimibe",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":399},{"trials":380,"activeCount":68},[],{"trials":382,"activeCount":68},[],{"trials":384,"activeCount":68},[],{"trials":386,"activeCount":68},[],{"trials":388,"activeCount":68},[389],{"nctId":390,"briefTitle":391,"status":313,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":205,"conditions":396,"interventions":398},"NCT01950884","Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis",[60],"2014-10","2014-12","2013-10",[397],"•Non-alcoholic Steatohepatitis (NASH)",[377],{"trials":400,"activeCount":68},[],{"intervention":402,"totalTrials":112,"cells":403},"Ethinylestradiol\u002FDienogest 0.03mg\u002F2mg",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":420},{"trials":405,"activeCount":68},[],{"trials":407,"activeCount":68},[],{"trials":409,"activeCount":68},[],{"trials":411,"activeCount":68},[],{"trials":413,"activeCount":68},[414],{"nctId":415,"briefTitle":416,"status":78,"phases":417,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":418,"interventions":419},"NCT06316206","The Use of Ethinylestradiol\u002FDienogest in Random Start Rapid Endometrial Preparation",[60],[26,28],[402],{"trials":421,"activeCount":68},[],{"intervention":423,"totalTrials":112,"cells":424},"1. alpha acid lipoic - tables",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":449},{"trials":426,"activeCount":68},[],{"trials":428,"activeCount":68},[],{"trials":430,"activeCount":68},[],{"trials":432,"activeCount":68},[],{"trials":434,"activeCount":68},[435],{"nctId":436,"briefTitle":437,"status":313,"phases":438,"primaryCompletion":439,"completion":440,"start":441,"enrollment":345,"conditions":442,"interventions":445},"NCT05211622","OZOCLO_MUCOSITIS: a New Protocol for Prevention of Oral Mucositis",[60],"2022-12-31","2023-01-10","2022-03-10",[443,444],"Mucositis (MeSH Unique ID: D052016)","Stomatitis (MeSH Unique ID: D013280)",[423,446,447,448],"2. ozonated oil - mouthwash","3. chlorhexidine 0,2% - mouthwash","4. sodium bicarbonate 5% solution - mouthwash",{"trials":450,"activeCount":68},[],{"intervention":446,"totalTrials":112,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":467},{"trials":454,"activeCount":68},[],{"trials":456,"activeCount":68},[],{"trials":458,"activeCount":68},[],{"trials":460,"activeCount":68},[],{"trials":462,"activeCount":68},[463],{"nctId":436,"briefTitle":437,"status":313,"phases":464,"primaryCompletion":439,"completion":440,"start":441,"enrollment":345,"conditions":465,"interventions":466},[60],[443,444],[423,446,447,448],{"trials":468,"activeCount":68},[],{"intervention":447,"totalTrials":112,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":479,"NA":485},{"trials":472,"activeCount":68},[],{"trials":474,"activeCount":68},[],{"trials":476,"activeCount":68},[],{"trials":478,"activeCount":68},[],{"trials":480,"activeCount":68},[481],{"nctId":436,"briefTitle":437,"status":313,"phases":482,"primaryCompletion":439,"completion":440,"start":441,"enrollment":345,"conditions":483,"interventions":484},[60],[443,444],[423,446,447,448],{"trials":486,"activeCount":68},[],{"intervention":448,"totalTrials":112,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":503},{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[],{"trials":494,"activeCount":68},[],{"trials":496,"activeCount":68},[],{"trials":498,"activeCount":68},[499],{"nctId":436,"briefTitle":437,"status":313,"phases":500,"primaryCompletion":439,"completion":440,"start":441,"enrollment":345,"conditions":501,"interventions":502},[60],[443,444],[423,446,447,448],{"trials":504,"activeCount":68},[],{"intervention":506,"totalTrials":112,"cells":507},"Drospirenone \u002F Estetrol",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":527},{"trials":509,"activeCount":68},[],{"trials":511,"activeCount":68},[],{"trials":513,"activeCount":68},[],{"trials":515,"activeCount":68},[],{"trials":517,"activeCount":68},[518],{"nctId":519,"briefTitle":520,"status":78,"phases":521,"primaryCompletion":342,"completion":343,"start":344,"enrollment":522,"conditions":523,"interventions":524},"NCT06324851","The Use of Drospirenone\u002FEstetrol, Nomegestrol Acetate\u002FEstradiol and Ethinylestradiol\u002FDienogest in Random Start Rapid Endometrial Preparation",[60],150,[26,28],[506,525,526],"Nomegestrol Acetate \u002F Estradiol","Ethinylestradiol \u002F Dienogest",{"trials":528,"activeCount":68},[],{"intervention":525,"totalTrials":112,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":68},[],{"trials":534,"activeCount":68},[],{"trials":536,"activeCount":68},[],{"trials":538,"activeCount":68},[],{"trials":540,"activeCount":68},[541],{"nctId":519,"briefTitle":520,"status":78,"phases":542,"primaryCompletion":342,"completion":343,"start":344,"enrollment":522,"conditions":543,"interventions":544},[60],[26,28],[506,525,526],{"trials":546,"activeCount":68},[],{"intervention":526,"totalTrials":112,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":563},{"trials":550,"activeCount":68},[],{"trials":552,"activeCount":68},[],{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[559],{"nctId":519,"briefTitle":520,"status":78,"phases":560,"primaryCompletion":342,"completion":343,"start":344,"enrollment":522,"conditions":561,"interventions":562},[60],[26,28],[506,525,526],{"trials":564,"activeCount":68},[],{"intervention":566,"totalTrials":112,"cells":567},"drospirenone\u002Festetrol 3mg\u002F14.2mg",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":584},{"trials":569,"activeCount":68},[],{"trials":571,"activeCount":68},[],{"trials":573,"activeCount":68},[],{"trials":575,"activeCount":68},[],{"trials":577,"activeCount":68},[578],{"nctId":579,"briefTitle":580,"status":78,"phases":581,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":582,"interventions":583},"NCT06316180","The Use of Drospirenone\u002FEstetrol in Random Start Rapid Endometrial Preparation",[60],[26,28],[566],{"trials":585,"activeCount":68},[],{"intervention":306,"totalTrials":112,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":602},{"trials":589,"activeCount":68},[],{"trials":591,"activeCount":68},[],{"trials":593,"activeCount":68},[],{"trials":595,"activeCount":68},[],{"trials":597,"activeCount":68},[598],{"nctId":296,"briefTitle":297,"status":78,"phases":599,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":600,"interventions":601},[60],[304],[306,307,308,282,309],{"trials":603,"activeCount":68},[],{"intervention":307,"totalTrials":112,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":620},{"trials":607,"activeCount":68},[],{"trials":609,"activeCount":68},[],{"trials":611,"activeCount":68},[],{"trials":613,"activeCount":68},[],{"trials":615,"activeCount":68},[616],{"nctId":296,"briefTitle":297,"status":78,"phases":617,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":618,"interventions":619},[60],[304],[306,307,308,282,309],{"trials":621,"activeCount":68},[],{"intervention":308,"totalTrials":112,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":638},{"trials":625,"activeCount":68},[],{"trials":627,"activeCount":68},[],{"trials":629,"activeCount":68},[],{"trials":631,"activeCount":68},[],{"trials":633,"activeCount":68},[634],{"nctId":296,"briefTitle":297,"status":78,"phases":635,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":636,"interventions":637},[60],[304],[306,307,308,282,309],{"trials":639,"activeCount":68},[],{"intervention":309,"totalTrials":112,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":656},{"trials":643,"activeCount":68},[],{"trials":645,"activeCount":68},[],{"trials":647,"activeCount":68},[],{"trials":649,"activeCount":68},[],{"trials":651,"activeCount":68},[652],{"nctId":296,"briefTitle":297,"status":78,"phases":653,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":654,"interventions":655},[60],[304],[306,307,308,282,309],{"trials":657,"activeCount":68},[],{"intervention":322,"totalTrials":112,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":68},[],{"trials":663,"activeCount":68},[],{"trials":665,"activeCount":68},[],{"trials":667,"activeCount":68},[],{"trials":669,"activeCount":68},[670],{"nctId":311,"briefTitle":312,"status":313,"phases":671,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":672,"interventions":673},[60],[320],[322,282],{"trials":675,"activeCount":68},[],{"intervention":677,"totalTrials":112,"cells":678},"Atorvastatin",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":700},{"trials":680,"activeCount":68},[],{"trials":682,"activeCount":68},[],{"trials":684,"activeCount":68},[],{"trials":686,"activeCount":68},[],{"trials":688,"activeCount":68},[689],{"nctId":690,"briefTitle":691,"status":78,"phases":692,"primaryCompletion":693,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":699},"NCT02225834","Atorvastatin in Acute Stroke Treatment",[60],"2014-01","2014-03","2011-11",50,[698],"Ischemic Stroke",[677],{"trials":701,"activeCount":68},[],{"intervention":703,"totalTrials":112,"cells":704},"Exenatide once weekly",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":713,"NA":724},{"trials":706,"activeCount":68},[],{"trials":708,"activeCount":68},[],{"trials":710,"activeCount":68},[],{"trials":712,"activeCount":68},[],{"trials":714,"activeCount":68},[715],{"nctId":716,"briefTitle":717,"status":78,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":95,"conditions":722,"interventions":723},"NCT02380521","Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes",[60],"2016-07","2016-11","2015-01",[320],[703],{"trials":725,"activeCount":68},[],{"intervention":727,"totalTrials":112,"cells":728},"Insulin Degludec \u002F Liraglutide Injectable Product",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":751},{"trials":730,"activeCount":68},[],{"trials":732,"activeCount":68},[],{"trials":734,"activeCount":68},[],{"trials":736,"activeCount":68},[],{"trials":738,"activeCount":68},[739],{"nctId":740,"briefTitle":741,"status":78,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":749},"NCT05360537","Effects of Degludec\u002FLiraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients",[60],"2021-12-01","2022-04-20","2021-04-01",100,[748],"Diabetes Mellitus, Type 2",[727,750],"Insulin Glargine",{"trials":752,"activeCount":68},[],{"intervention":750,"totalTrials":112,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":769},{"trials":756,"activeCount":68},[],{"trials":758,"activeCount":68},[],{"trials":760,"activeCount":68},[],{"trials":762,"activeCount":68},[],{"trials":764,"activeCount":68},[765],{"nctId":740,"briefTitle":741,"status":78,"phases":766,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":767,"interventions":768},[60],[748],[727,750],{"trials":770,"activeCount":68},[],{"intervention":772,"totalTrials":112,"cells":773},"Vitamin D",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":792,"NA":794},{"trials":775,"activeCount":68},[],{"trials":777,"activeCount":68},[],{"trials":779,"activeCount":68},[],{"trials":781,"activeCount":68},[782],{"nctId":783,"briefTitle":784,"status":313,"phases":785,"primaryCompletion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT01623024","Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis",[59],"2014-09","2012-09",200,[790],"Non.Alcoholic Fatty Liver Disease",[772],{"trials":793,"activeCount":68},[],{"trials":795,"activeCount":68},[],{"intervention":797,"totalTrials":112,"cells":798},"dual-release hydrocortisone",{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":819,"NA":821},{"trials":800,"activeCount":68},[],{"trials":802,"activeCount":68},[],{"trials":804,"activeCount":68},[],{"trials":806,"activeCount":68},[807],{"nctId":808,"briefTitle":809,"status":78,"phases":810,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":817},"NCT06260462","Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency",[59],"2022-09-30","2023-12-30","2012-01-01",88,[816],"Adrenal Insufficiency",[797,818],"Conventional glucocortidois",{"trials":820,"activeCount":68},[],{"trials":822,"activeCount":68},[],{"intervention":818,"totalTrials":112,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":837,"NA":839},{"trials":826,"activeCount":68},[],{"trials":828,"activeCount":68},[],{"trials":830,"activeCount":68},[],{"trials":832,"activeCount":68},[833],{"nctId":808,"briefTitle":809,"status":78,"phases":834,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":835,"interventions":836},[59],[816],[797,818],{"trials":838,"activeCount":68},[],{"trials":840,"activeCount":68},[],{"intervention":842,"totalTrials":112,"cells":843},"intravenous furosemide",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":845,"activeCount":68},[],{"trials":847,"activeCount":68},[],{"trials":849,"activeCount":68},[850],{"nctId":851,"briefTitle":852,"status":78,"phases":853,"primaryCompletion":854,"completion":855,"start":856,"enrollment":275,"conditions":857,"interventions":860},"NCT02821377","Metabolic Effects of Furosemide +HSS in Refractory Ascites",[58],"2015-12","2016-04","2013-12",[858,859],"Ascites","Cirrhosis",[842,861],"Hypertonic saline solutions",{"trials":863,"activeCount":68},[],{"trials":865,"activeCount":68},[],{"trials":867,"activeCount":68},[],{"intervention":861,"totalTrials":112,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":871,"activeCount":68},[],{"trials":873,"activeCount":68},[],{"trials":875,"activeCount":68},[876],{"nctId":851,"briefTitle":852,"status":78,"phases":877,"primaryCompletion":854,"completion":855,"start":856,"enrollment":275,"conditions":878,"interventions":879},[58],[858,859],[842,861],{"trials":881,"activeCount":68},[],{"trials":883,"activeCount":68},[],{"trials":885,"activeCount":68},[],{"intervention":887,"totalTrials":112,"cells":888},"OxigenOzone_Insufflation",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":890,"activeCount":68},[],{"trials":892,"activeCount":68},[],{"trials":894,"activeCount":68},[895],{"nctId":896,"briefTitle":897,"status":78,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT06072404","OZONE_EXO: Comparative Analysis of Protocols for Dental Exactions in Patients at Risk of MRONJ: Case-control Study",[57,58],"2020-03-30","2018-02-01",117,[903],"MEDICATION RELATED OSTEONECROSIS OF THE JAW",[887],{"trials":906,"activeCount":68},[],{"trials":908,"activeCount":68},[],{"trials":910,"activeCount":68},[],{"intervention":912,"totalTrials":112,"cells":913},"OZOPROMAF_SEQ1",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":915,"activeCount":68},[],{"trials":917,"activeCount":68},[],{"trials":919,"activeCount":68},[920],{"nctId":921,"briefTitle":922,"status":923,"phases":924,"primaryCompletion":925,"completion":926,"start":900,"enrollment":696,"conditions":927,"interventions":928},"NCT05036837","Infiltration of Medical Ozone for the Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)","SUSPENDED",[57,58],"2020-03-01","2022-03-01",[903],[912],{"trials":930,"activeCount":68},[],{"trials":932,"activeCount":68},[],{"trials":934,"activeCount":68},[],{"intervention":936,"totalTrials":283,"cells":937},"growth hormone",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":957,"NA":959},{"trials":939,"activeCount":68},[],{"trials":941,"activeCount":68},[],{"trials":943,"activeCount":68},[],{"trials":945,"activeCount":68},[946],{"nctId":947,"briefTitle":948,"status":78,"phases":949,"primaryCompletion":950,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":955},"NCT03033121","Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children",[59],"2017-01-01","2016-01-01",32,[954],"Growth Hormone Treatment",[956],"Growth Hormone",{"trials":958,"activeCount":68},[],{"trials":960,"activeCount":68},[961],{"nctId":962,"briefTitle":963,"status":78,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT03203356","Adrenal Function in GHD Children",[],"2017-05-01","2017-05-30","2016-05-30",30,[954,970],"Adrenal; Functional Disturbance",[936],{"intervention":973,"totalTrials":112,"cells":974},"Drospirenone 4 MG",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":976,"activeCount":68},[],{"trials":978,"activeCount":68},[],{"trials":980,"activeCount":68},[],{"trials":982,"activeCount":68},[],{"trials":984,"activeCount":68},[],{"trials":986,"activeCount":68},[987],{"nctId":988,"briefTitle":989,"status":313,"phases":990,"primaryCompletion":103,"completion":991,"start":812,"enrollment":275,"conditions":992,"interventions":994},"NCT06174792","Evaluation of the Efficacy and Safety of Drospirenone in the Treatment of Adenomyosis",[],"2024-12",[993],"Adenomyosis",[973],{"intervention":996,"totalTrials":112,"cells":997},"Misoprostol",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":999,"activeCount":68},[],{"trials":1001,"activeCount":68},[],{"trials":1003,"activeCount":68},[],{"trials":1005,"activeCount":68},[],{"trials":1007,"activeCount":68},[],{"trials":1009,"activeCount":68},[1010],{"nctId":1011,"briefTitle":1012,"status":313,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1020},"NCT06184139","Effect of Maternal Age and BMI on Induction of Labor Using Oral Misoprostol in Late-term Pregnancies: a Retrospective Cross-sectional Study",[],"2024-01","2023-12",104,[1018,1019],"Induction of Labor Affected Fetus \u002F Newborn","Pregnancy Late",[996],{"intervention":1022,"totalTrials":112,"cells":1023},"KIR genotyping",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1025,"activeCount":68},[],{"trials":1027,"activeCount":68},[],{"trials":1029,"activeCount":68},[],{"trials":1031,"activeCount":68},[],{"trials":1033,"activeCount":68},[],{"trials":1035,"activeCount":68},[1036],{"nctId":1037,"briefTitle":1038,"status":78,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1045},"NCT05469971","KIR Genes and Non-Celiac Wheat Sensitivity",[],"2023-06-30","2023-09-30","2022-11-01",170,[15],[1022],{"intervention":1047,"totalTrials":112,"cells":1048},"Oral semaglutide",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1050,"activeCount":68},[],{"trials":1052,"activeCount":68},[],{"trials":1054,"activeCount":68},[],{"trials":1056,"activeCount":68},[],{"trials":1058,"activeCount":68},[],{"trials":1060,"activeCount":68},[1061],{"nctId":1062,"briefTitle":1063,"status":78,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1071},"NCT07056803","Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus",[],"2024-06-25","2025-06-25","2024-01-01",212,[1070],"Diabetes Mellitus Type 2",[1047,1072],"subcutaneous semaglutide",{"intervention":1072,"totalTrials":112,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1076,"activeCount":68},[],{"trials":1078,"activeCount":68},[],{"trials":1080,"activeCount":68},[],{"trials":1082,"activeCount":68},[],{"trials":1084,"activeCount":68},[],{"trials":1086,"activeCount":68},[1087],{"nctId":1062,"briefTitle":1063,"status":78,"phases":1088,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1089,"interventions":1090},[],[1070],[1047,1072]]